个人中心 - 老虎社区

nctony

IP属地：未知

帖子 · 617帖子 · 617
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- nctonynctony
  ·2022-01-28
  $Unity Software Inc.(U)$U is a good buy at this price[Miser]
  2,149 评论
  点赞
  分享
  举报
- nctonynctony
  ·2022-01-19
  Still strong,one of the stock I'm looking at[Cool]
  UnitedHealth Group Q4 EPS $4.48 Beats $4.31 Est; Revenue $73.74B Beats $72.75B Est
  UnitedHealth Group Q4 EPS $4.48 Beats $4.31 Est; Revenue $73.74B Beats $72.75B Est
  UnitedHealth Group Q4 EPS $4.48 Beats $4.31 Est; Revenue $73.74B Beats $72.75B Est
  1,862 评论
  点赞
  分享
  举报
- nctonynctony
  ·2021-12-28
  Agent Doing no up lol[Spurting]
  非常抱歉，此主贴已删除
  2,011 评论
  3
  分享
  举报
- nctonynctony
  ·2021-12-28
  When is our share rising[Surprised]
  非常抱歉，此主贴已删除
  1,931 评论
  4
  分享
  举报
- nctonynctony
  ·2021-12-25
  Time to buy for the medication[Cry]
  非常抱歉，此主贴已删除
  2,229 评论
  2
  分享
  举报
- nctonynctony
  ·2021-12-23
  Below 105 is a good buy[Cool]
  非常抱歉，此主贴已删除
  1,564 评论
  点赞
  分享
  举报
- nctonynctony
  ·2021-12-23
  I'm in[Miser]
  Grab Stock May Be Down But It Isn’t Out
  When Southeast Asian ride-hailing and delivery company Grab Holdings(NASDAQ:GRAB) completed a revers
  Grab Stock May Be Down But It Isn’t Out
  1,288 评论
  4
  分享
  举报
- nctonynctony
  ·2021-12-23
  Bankruptcy[Cry]
  Allakos slumps 87%, draws analysts downgrade on 'disappointing' lirentelimab data
  Allakos continues to slide, falls 87.4% premarket following yesterday's announcement that its late-s
  Allakos slumps 87%, draws analysts downgrade on 'disappointing' lirentelimab data
  2,016 评论
  1
  分享
  举报
- nctonynctony
  ·2021-12-22
  But my Sheng Siong not moving lol[Facepalm]
  非常抱歉，此主贴已删除
  1,649 评论
  5
  分享
  举报
- nctonynctony
  ·2021-12-21
  His tax money enough for me to spent[Cool]
  非常抱歉，此主贴已删除
  2,044 评论
  1
  分享
  举报

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3557024931927052","uuid":"3557024931927052","gmtCreate":1593930909433,"gmtModify":1607686960593,"name":"nctony","pinyin":"nctony","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/1449dfc5089ded0e8efe303fd4dd43b1","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":126,"headSize":492,"tweetSize":617,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":1,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"228c86a078844d74991fff2b7ab2428d-1","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资经理虎","description":"证券账户累计交易金额达到10万美元","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.21%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.04.02","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"93.91%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":639226789,"gmtCreate":1643325211853,"gmtModify":1643325213106,"author":{"id":"3557024931927052","authorId":"3557024931927052","name":"nctony","avatar":"https://static.tigerbbs.com/1449dfc5089ded0e8efe303fd4dd43b1","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3557024931927052","authorIdStr":"3557024931927052"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/U\">$Unity Software Inc.(U)$</a>U is a good buy at this price[Miser]&nbsp;","listText":"<a href=\"https://laohu8.com/S/U\">$Unity Software Inc.(U)$</a>U is a good buy at this price[Miser]&nbsp;","text":"$Unity Software Inc.(U)$U is a good buy at this price[Miser]","images":[{"img":"https://static.tigerbbs.com/d4e8ebc88a989c867e04d0239af7b6f5","width":"1080","height":"3501"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/639226789","isVote":1,"tweetType":1,"viewCount":2149,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":697763009,"gmtCreate":1642596163735,"gmtModify":1642596169495,"author":{"id":"3557024931927052","authorId":"3557024931927052","name":"nctony","avatar":"https://static.tigerbbs.com/1449dfc5089ded0e8efe303fd4dd43b1","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3557024931927052","authorIdStr":"3557024931927052"},"themes":[],"htmlText":"Still strong,one of the stock I'm looking at[Cool]&nbsp;","listText":"Still strong,one of the stock I'm looking at[Cool]&nbsp;","text":"Still strong,one of the stock I'm looking at[Cool]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/697763009","repostId":"2204030837","repostType":2,"repost":{"id":"2204030837","kind":"highlight","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1642593427,"share":"https://www.laohunote.com/m/news/2204030837?lang=&edition=full","pubTime":"2022-01-19 19:57","market":"us","language":"en","title":"UnitedHealth Group  Q4 EPS $4.48 Beats $4.31 Est; Revenue $73.74B Beats $72.75B Est","url":"https://stock-news.laohu8.com/highlight/detail?id=2204030837","media":"Benzinga","summary":"UnitedHealth Group  Q4 EPS $4.48 Beats $4.31 Est; Revenue $73.74B Beats $72.75B Est","content":"<html><body><p>UnitedHealth Group  Q4 EPS $4.48 Beats $4.31 Est; Revenue $73.74B Beats $72.75B Est</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UnitedHealth Group  Q4 EPS $4.48 Beats $4.31 Est; Revenue $73.74B Beats $72.75B Est</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUnitedHealth Group  Q4 EPS $4.48 Beats $4.31 Est; Revenue $73.74B Beats $72.75B Est\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2022-01-19 19:57</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>UnitedHealth Group  Q4 EPS $4.48 Beats $4.31 Est; Revenue $73.74B Beats $72.75B Est</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"UNH":"联合健康"},"source_url":"https://www.benzinga.com/news/earnings/22/01/25103432/unitedhealth-group-q4-eps-4-48-beats-4-31-est-revenue-73-74b-beats-72-75b-est","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2204030837","content_text":"UnitedHealth Group  Q4 EPS $4.48 Beats $4.31 Est; Revenue $73.74B Beats $72.75B Est","news_type":1},"isVote":1,"tweetType":1,"viewCount":1862,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":696620981,"gmtCreate":1640685409434,"gmtModify":1640685655589,"author":{"id":"3557024931927052","authorId":"3557024931927052","name":"nctony","avatar":"https://static.tigerbbs.com/1449dfc5089ded0e8efe303fd4dd43b1","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3557024931927052","authorIdStr":"3557024931927052"},"themes":[],"htmlText":"Agent Doing no up lol[Spurting]&nbsp;","listText":"Agent Doing no up lol[Spurting]&nbsp;","text":"Agent Doing no up lol[Spurting]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/696620981","repostId":"1137889275","repostType":2,"isVote":1,"tweetType":1,"viewCount":2011,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":696194139,"gmtCreate":1640647423003,"gmtModify":1640647424245,"author":{"id":"3557024931927052","authorId":"3557024931927052","name":"nctony","avatar":"https://static.tigerbbs.com/1449dfc5089ded0e8efe303fd4dd43b1","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3557024931927052","authorIdStr":"3557024931927052"},"themes":[],"htmlText":"When is our share rising[Surprised]&nbsp;","listText":"When is our share rising[Surprised]&nbsp;","text":"When is our share rising[Surprised]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/696194139","repostId":"1127544468","repostType":2,"isVote":1,"tweetType":1,"viewCount":1931,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698665932,"gmtCreate":1640387115026,"gmtModify":1640387116266,"author":{"id":"3557024931927052","authorId":"3557024931927052","name":"nctony","avatar":"https://static.tigerbbs.com/1449dfc5089ded0e8efe303fd4dd43b1","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3557024931927052","authorIdStr":"3557024931927052"},"themes":[],"htmlText":"Time to buy for the medication[Cry]&nbsp;","listText":"Time to buy for the medication[Cry]&nbsp;","text":"Time to buy for the medication[Cry]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698665932","repostId":"2193127176","repostType":4,"isVote":1,"tweetType":1,"viewCount":2229,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698001007,"gmtCreate":1640253722488,"gmtModify":1640254213662,"author":{"id":"3557024931927052","authorId":"3557024931927052","name":"nctony","avatar":"https://static.tigerbbs.com/1449dfc5089ded0e8efe303fd4dd43b1","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3557024931927052","authorIdStr":"3557024931927052"},"themes":[],"htmlText":"Below 105 is a good buy[Cool]&nbsp;","listText":"Below 105 is a good buy[Cool]&nbsp;","text":"Below 105 is a good buy[Cool]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698001007","repostId":"2193138080","repostType":2,"isVote":1,"tweetType":1,"viewCount":1564,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691714127,"gmtCreate":1640243368473,"gmtModify":1640243377928,"author":{"id":"3557024931927052","authorId":"3557024931927052","name":"nctony","avatar":"https://static.tigerbbs.com/1449dfc5089ded0e8efe303fd4dd43b1","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3557024931927052","authorIdStr":"3557024931927052"},"themes":[],"htmlText":"I'm in[Miser]&nbsp;","listText":"I'm in[Miser]&nbsp;","text":"I'm in[Miser]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691714127","repostId":"1184389618","repostType":4,"repost":{"id":"1184389618","kind":"news","pubTimestamp":1640230223,"share":"https://www.laohunote.com/m/news/1184389618?lang=&edition=full","pubTime":"2021-12-23 11:30","market":"us","language":"en","title":"Grab Stock May Be Down But It Isn’t Out","url":"https://stock-news.laohu8.com/highlight/detail?id=1184389618","media":"InvestorPlace","summary":"When Southeast Asian ride-hailing and delivery company Grab Holdings(NASDAQ:GRAB) completed a revers","content":"<p>When Southeast Asian ride-hailing and delivery company&nbsp;<b>Grab Holdings</b>(NASDAQ:<b><u>GRAB</u></b>) completed a reverse merger with special purpose acquisition company Altimeter Growth Corp. in early December it made history as the largest company to go public via a SPAC merger. Yet, this didn’t stop GRAB stock from&nbsp;plummeting more than 20%&nbsp;on the day of the merger.</p>\n<p>Since then, investors have continued to give GRAB stock the cold shoulder, with shares falling another 16% to trade at $7.34 at the time of this writing.</p>\n<p>Now, before you write off an investment in Grab Holdings, consider that the company is still in the early innings and let’s consider where GRAB stock could go from here.</p>\n<p><b>What’s Behind Grab’s Cool Reception?</b></p>\n<p>Grab is the largest ride-hailing and delivery company in Southeast Asia, with&nbsp;operations in Singapore,&nbsp;Malaysia, Cambodia,&nbsp;Indonesia, Myanmar,&nbsp;Philippines,&nbsp;Thailand and Vietnam and serving more than 187 million users.</p>\n<p>There are a number of plausible explanations for why GRAB stock has not been well-received by investors.</p>\n<p>For starters, growth estimates for the Southeast Asian region have been lowered recently primarily due to the coronavirus pandemic. In September, the Asian Development Bank&nbsp;dropped its 2021 growth forecast&nbsp;for the region to 3.1% from 4.4% previously.</p>\n<p>Widespread lockdowns in the region due to recurring waves of COVID-19 have hurt demand for Grab’s ride-hailing services and weighed on revenue despite an increase in food-delivery volumes.</p>\n<p>Grab reported its&nbsp;third-quarter results&nbsp;on Nov. 11. Revenue fell 9% year over year to $157 million, with the company citing “a decline in mobility due to the severe lockdowns in Vietnam.” Falling revenue is obviously not something investors want to see, especially from a company that has yet to turn a profit.</p>\n<p>Yet, the company did report a 32% year-over-year increase in gross merchandise value, with the dollar value of transactions from Grab’s services rising to $4.04 billion thanks to strength in the company’s deliveries segment.</p>\n<p><b>There’s Reason for Optimism</b></p>\n<p>The deal to go public through the merger with Altimeter Growth Corp. valued Grab at close to $40 billion, which as I mentioned, was a record. The fact that three weeks later GRAB stock has a market cap of about $27.5 billion tells us that perhaps things got a bit too heated. However, there is reason for optimism.</p>\n<p>The ride-hailing platform has secured the backing of significant players across related industries, including&nbsp;<b>DiDi Global</b>(NYSE:<b><u>DIDI</u></b>),<b>Toyota</b>(NYSE:<b><u>TM</u></b>) and&nbsp;<b>SoftBank’s</b>(OTCMKTS:<b><u>SFTBY</u></b>) Vision Fund.</p>\n<p>Grab Holdings also has some positive catalysts on the horizon. For example, the company recently announced that it&nbsp;will be purchasing&nbsp;<b>Jaya Grocer</b>, a premium supermarket chain in Malaysia.</p>\n<p>This acquisition fits nicely with the ride-hailing and delivery business model the company seeks to expand. Management refers to the model as a “superapp” focus, whereby users can access multiple services in a single, convenient location.</p>\n<p><b>The Bottom Line on GRAB Stock</b></p>\n<p>I can’t say Grab Holdings can immediately turn things around. But its potential in the burgeoning Southeast Asian market means it remains relevant and has a long runway.</p>\n<p>Of the six analysts following GRAB stock, two rate it a “buy” and there are no “sell” ratings,according to&nbsp;<i>The Wall Street Journal</i>. Meanwhile, the consensus price target stands at $12.25, which represents upside of 67% from current levels.</p>\n<p>GRAB stock is very cheap now, so it’s hardly a dangerous speculative play. There’s a good argument to be made for investing now and hoping that the company continues to expand its footprint. Profitability should follow.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Grab Stock May Be Down But It Isn’t Out</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGrab Stock May Be Down But It Isn’t Out\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-23 11:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/12/grab-stock-may-be-down-but-it-isnt-out/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When Southeast Asian ride-hailing and delivery company Grab Holdings(NASDAQ:GRAB) completed a reverse merger with special purpose acquisition company Altimeter Growth Corp. in early December it made ...</p>\n\n<a href=\"https://investorplace.com/2021/12/grab-stock-may-be-down-but-it-isnt-out/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GRAB":"Grab Holdings"},"source_url":"https://investorplace.com/2021/12/grab-stock-may-be-down-but-it-isnt-out/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1184389618","content_text":"When Southeast Asian ride-hailing and delivery company Grab Holdings(NASDAQ:GRAB) completed a reverse merger with special purpose acquisition company Altimeter Growth Corp. in early December it made history as the largest company to go public via a SPAC merger. Yet, this didn’t stop GRAB stock from plummeting more than 20% on the day of the merger.\nSince then, investors have continued to give GRAB stock the cold shoulder, with shares falling another 16% to trade at $7.34 at the time of this writing.\nNow, before you write off an investment in Grab Holdings, consider that the company is still in the early innings and let’s consider where GRAB stock could go from here.\nWhat’s Behind Grab’s Cool Reception?\nGrab is the largest ride-hailing and delivery company in Southeast Asia, with operations in Singapore, Malaysia, Cambodia, Indonesia, Myanmar, Philippines, Thailand and Vietnam and serving more than 187 million users.\nThere are a number of plausible explanations for why GRAB stock has not been well-received by investors.\nFor starters, growth estimates for the Southeast Asian region have been lowered recently primarily due to the coronavirus pandemic. In September, the Asian Development Bank dropped its 2021 growth forecast for the region to 3.1% from 4.4% previously.\nWidespread lockdowns in the region due to recurring waves of COVID-19 have hurt demand for Grab’s ride-hailing services and weighed on revenue despite an increase in food-delivery volumes.\nGrab reported its third-quarter results on Nov. 11. Revenue fell 9% year over year to $157 million, with the company citing “a decline in mobility due to the severe lockdowns in Vietnam.” Falling revenue is obviously not something investors want to see, especially from a company that has yet to turn a profit.\nYet, the company did report a 32% year-over-year increase in gross merchandise value, with the dollar value of transactions from Grab’s services rising to $4.04 billion thanks to strength in the company’s deliveries segment.\nThere’s Reason for Optimism\nThe deal to go public through the merger with Altimeter Growth Corp. valued Grab at close to $40 billion, which as I mentioned, was a record. The fact that three weeks later GRAB stock has a market cap of about $27.5 billion tells us that perhaps things got a bit too heated. However, there is reason for optimism.\nThe ride-hailing platform has secured the backing of significant players across related industries, including DiDi Global(NYSE:DIDI),Toyota(NYSE:TM) and SoftBank’s(OTCMKTS:SFTBY) Vision Fund.\nGrab Holdings also has some positive catalysts on the horizon. For example, the company recently announced that it will be purchasing Jaya Grocer, a premium supermarket chain in Malaysia.\nThis acquisition fits nicely with the ride-hailing and delivery business model the company seeks to expand. Management refers to the model as a “superapp” focus, whereby users can access multiple services in a single, convenient location.\nThe Bottom Line on GRAB Stock\nI can’t say Grab Holdings can immediately turn things around. But its potential in the burgeoning Southeast Asian market means it remains relevant and has a long runway.\nOf the six analysts following GRAB stock, two rate it a “buy” and there are no “sell” ratings,according to The Wall Street Journal. Meanwhile, the consensus price target stands at $12.25, which represents upside of 67% from current levels.\nGRAB stock is very cheap now, so it’s hardly a dangerous speculative play. There’s a good argument to be made for investing now and hoping that the company continues to expand its footprint. Profitability should follow.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1288,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691216475,"gmtCreate":1640195777903,"gmtModify":1640195779137,"author":{"id":"3557024931927052","authorId":"3557024931927052","name":"nctony","avatar":"https://static.tigerbbs.com/1449dfc5089ded0e8efe303fd4dd43b1","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3557024931927052","authorIdStr":"3557024931927052"},"themes":[],"htmlText":"Bankruptcy[Cry]&nbsp;","listText":"Bankruptcy[Cry]&nbsp;","text":"Bankruptcy[Cry]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691216475","repostId":"1163953446","repostType":2,"repost":{"id":"1163953446","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1640182473,"share":"https://www.laohunote.com/m/news/1163953446?lang=&edition=full","pubTime":"2021-12-22 22:14","market":"us","language":"en","title":"Allakos slumps 87%, draws analysts downgrade on 'disappointing' lirentelimab data","url":"https://stock-news.laohu8.com/highlight/detail?id=1163953446","media":"Tiger Newspress","summary":"Allakos continues to slide, falls 87.4% premarket following yesterday's announcement that its late-s","content":"<p>Allakos&nbsp;continues to slide,&nbsp;falls 87.4% premarket&nbsp;following yesterday's announcement that its late-stage studies, KRYPTOS and ENIGMA 2failed to achieve statistical significance.</p>\n<p><img src=\"https://static.tigerbbs.com/961eae374dfe4dd479394caaf470012c\" tg-width=\"714\" tg-height=\"590\" width=\"100%\" height=\"auto\"></p>\n<p>The studies met their histologic co-primary endpoints but failed to achieve symptomatic endpoints.</p>\n<p>In ENIGMA, patients treated with lirentelimab achieved a 10.0-point reduction in Total Symptom Score-6 (TSS-6) at weeks 23-24 from baseline (baseline = 29.5) compared to an 11.5-point reduction in the placebo group (baseline = 27.7; p=0.343).</p>\n<p>On the second co-primary endpoint of absolute mean change in patient reported Dysphagia Symptom Questionnaire in KRYPTOS trial, the high-dose group achieved a 17.4-point reduction, the low-dose group achieved an 11.9-point reduction and placebo achieved a 14.6-point reduction.</p>\n<p>Following this disappointing result, several analysts lowered their ratings of the stock and slashed the price targets.</p>\n<p>William Blair downgraded the stock to Market Perform from Outperform.</p>\n<p>Analysts of the firm say, \"while we believe lirentelimab has shown clear evidence of histologic activity against eosinophils and mast cells, the failure to achieve co-primary endpoints of patient reported symptoms in both studies raises questions about whether these histologic improvements can translate into clinical improvements.\"</p>\n<p>With lirentelimab performing worse than placebo, there are clearly questions as to why the clean results in Phase II didn’t translate, the analyst notes.</p>\n<p>Cowen analyst Joseph Thome has also cut the recommendation on Allakos to Market Perform from Outperform without the price target (PT) pending pipeline clarity.</p>\n<p>SVB Leerink analyst Thomas Smith downgraded the stock to Market Perform from Outperform, with PT of $17.</p>\n<p>Barclays analyst Carter Gould lowered the firm's PT on Allakos to $8 from $36 and keeps an Underweight rating. The company's lead asset failed in key Phase 3 studies, Gould tells investors in a research note. He views this as the \"end game\" for lirentelimab.</p>\n<p>Morgan Stanley says Allakos' disappointing data increase&nbsp;eosinophilic gastrointestinal diseases (EGIDs) uncertainty.</p>\n<p>Jefferies analyst Maury Raycroft cut the recommendation on&nbsp;Allakos&nbsp;to Hold from Buy.</p>\n<p>LifeSci Capital analyst Samuel Slutsky downgraded the stock to Market Perform from Outperform.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Allakos slumps 87%, draws analysts downgrade on 'disappointing' lirentelimab data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAllakos slumps 87%, draws analysts downgrade on 'disappointing' lirentelimab data\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-22 22:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Allakos&nbsp;continues to slide,&nbsp;falls 87.4% premarket&nbsp;following yesterday's announcement that its late-stage studies, KRYPTOS and ENIGMA 2failed to achieve statistical significance.</p>\n<p><img src=\"https://static.tigerbbs.com/961eae374dfe4dd479394caaf470012c\" tg-width=\"714\" tg-height=\"590\" width=\"100%\" height=\"auto\"></p>\n<p>The studies met their histologic co-primary endpoints but failed to achieve symptomatic endpoints.</p>\n<p>In ENIGMA, patients treated with lirentelimab achieved a 10.0-point reduction in Total Symptom Score-6 (TSS-6) at weeks 23-24 from baseline (baseline = 29.5) compared to an 11.5-point reduction in the placebo group (baseline = 27.7; p=0.343).</p>\n<p>On the second co-primary endpoint of absolute mean change in patient reported Dysphagia Symptom Questionnaire in KRYPTOS trial, the high-dose group achieved a 17.4-point reduction, the low-dose group achieved an 11.9-point reduction and placebo achieved a 14.6-point reduction.</p>\n<p>Following this disappointing result, several analysts lowered their ratings of the stock and slashed the price targets.</p>\n<p>William Blair downgraded the stock to Market Perform from Outperform.</p>\n<p>Analysts of the firm say, \"while we believe lirentelimab has shown clear evidence of histologic activity against eosinophils and mast cells, the failure to achieve co-primary endpoints of patient reported symptoms in both studies raises questions about whether these histologic improvements can translate into clinical improvements.\"</p>\n<p>With lirentelimab performing worse than placebo, there are clearly questions as to why the clean results in Phase II didn’t translate, the analyst notes.</p>\n<p>Cowen analyst Joseph Thome has also cut the recommendation on Allakos to Market Perform from Outperform without the price target (PT) pending pipeline clarity.</p>\n<p>SVB Leerink analyst Thomas Smith downgraded the stock to Market Perform from Outperform, with PT of $17.</p>\n<p>Barclays analyst Carter Gould lowered the firm's PT on Allakos to $8 from $36 and keeps an Underweight rating. The company's lead asset failed in key Phase 3 studies, Gould tells investors in a research note. He views this as the \"end game\" for lirentelimab.</p>\n<p>Morgan Stanley says Allakos' disappointing data increase&nbsp;eosinophilic gastrointestinal diseases (EGIDs) uncertainty.</p>\n<p>Jefferies analyst Maury Raycroft cut the recommendation on&nbsp;Allakos&nbsp;to Hold from Buy.</p>\n<p>LifeSci Capital analyst Samuel Slutsky downgraded the stock to Market Perform from Outperform.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1163953446","content_text":"Allakos continues to slide, falls 87.4% premarket following yesterday's announcement that its late-stage studies, KRYPTOS and ENIGMA 2failed to achieve statistical significance.\n\nThe studies met their histologic co-primary endpoints but failed to achieve symptomatic endpoints.\nIn ENIGMA, patients treated with lirentelimab achieved a 10.0-point reduction in Total Symptom Score-6 (TSS-6) at weeks 23-24 from baseline (baseline = 29.5) compared to an 11.5-point reduction in the placebo group (baseline = 27.7; p=0.343).\nOn the second co-primary endpoint of absolute mean change in patient reported Dysphagia Symptom Questionnaire in KRYPTOS trial, the high-dose group achieved a 17.4-point reduction, the low-dose group achieved an 11.9-point reduction and placebo achieved a 14.6-point reduction.\nFollowing this disappointing result, several analysts lowered their ratings of the stock and slashed the price targets.\nWilliam Blair downgraded the stock to Market Perform from Outperform.\nAnalysts of the firm say, \"while we believe lirentelimab has shown clear evidence of histologic activity against eosinophils and mast cells, the failure to achieve co-primary endpoints of patient reported symptoms in both studies raises questions about whether these histologic improvements can translate into clinical improvements.\"\nWith lirentelimab performing worse than placebo, there are clearly questions as to why the clean results in Phase II didn’t translate, the analyst notes.\nCowen analyst Joseph Thome has also cut the recommendation on Allakos to Market Perform from Outperform without the price target (PT) pending pipeline clarity.\nSVB Leerink analyst Thomas Smith downgraded the stock to Market Perform from Outperform, with PT of $17.\nBarclays analyst Carter Gould lowered the firm's PT on Allakos to $8 from $36 and keeps an Underweight rating. The company's lead asset failed in key Phase 3 studies, Gould tells investors in a research note. He views this as the \"end game\" for lirentelimab.\nMorgan Stanley says Allakos' disappointing data increase eosinophilic gastrointestinal diseases (EGIDs) uncertainty.\nJefferies analyst Maury Raycroft cut the recommendation on Allakos to Hold from Buy.\nLifeSci Capital analyst Samuel Slutsky downgraded the stock to Market Perform from Outperform.","news_type":1},"isVote":1,"tweetType":1,"viewCount":2016,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691865274,"gmtCreate":1640168185744,"gmtModify":1640168191155,"author":{"id":"3557024931927052","authorId":"3557024931927052","name":"nctony","avatar":"https://static.tigerbbs.com/1449dfc5089ded0e8efe303fd4dd43b1","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3557024931927052","authorIdStr":"3557024931927052"},"themes":[],"htmlText":"But my Sheng Siong not moving lol[Facepalm]&nbsp;","listText":"But my Sheng Siong not moving lol[Facepalm]&nbsp;","text":"But my Sheng Siong not moving lol[Facepalm]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691865274","repostId":"1143400646","repostType":2,"isVote":1,"tweetType":1,"viewCount":1649,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693721482,"gmtCreate":1640084499766,"gmtModify":1640084501000,"author":{"id":"3557024931927052","authorId":"3557024931927052","name":"nctony","avatar":"https://static.tigerbbs.com/1449dfc5089ded0e8efe303fd4dd43b1","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3557024931927052","authorIdStr":"3557024931927052"},"themes":[],"htmlText":"His tax money enough for me to spent[Cool]&nbsp;","listText":"His tax money enough for me to spent[Cool]&nbsp;","text":"His tax money enough for me to spent[Cool]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/693721482","repostId":"1163497621","repostType":2,"isVote":1,"tweetType":1,"viewCount":2044,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"posts","isTTM":false}